Table II.
Clinical parameters and progress of patients who maintained low-dose safinamide (50 mg/day) (n = 45).
| Start | Six months | p | |
|---|---|---|---|
| Morning akinesia, % | 75.6 | 44.2 | 0.026 |
|
| |||
| Nocturnal akinesia, % | 20 | 12.5 | 0.046 |
|
| |||
| Wearing off, % | 57.8 | 25.6 | 0.001 |
|
| |||
| Unpredictable off, % | 6.8 | 4.4 | <0.001 |
|
| |||
| UPDRS-III | 25.59 (SD: 11.69) | 20.89 (SD: 11.52) | <0.001 |
|
| |||
| CGI, % | |||
| Better | 65.1 | ||
| Equal | 30.2 | ||
| Worse | 4.7 | ||
CGI: Clinical Global Impression; SD: standard deviation; UPDRS: Unified Parkinson’s Disease Rating Scale.